

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2018 May 7; 24(17): 1825-1924





### REVIEW

- 1825 Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?  
*Moreno-Cubero E, Sánchez del Arco RT, Peña-Asensio J, Sanz de Villalobos E, Miquel J, Larrubia JR*
- 1839 Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma  
*Mukaida N, Nakamoto Y*

### MINIREVIEWS

- 1859 Endoscopic management of Crohn's strictures  
*Bessissow T, Reinglas J, Aruljothy A, Lakatos PL, Van Assche G*
- 1868 Anti-integrin therapy for inflammatory bowel disease  
*Park SC, Jeon YT*
- 1881 Olfactomedin-4 in digestive diseases: A mini-review  
*Wang XY, Chen SH, Zhang YN, Xu CF*

### ORIGINAL ARTICLE

#### Basic Study

- 1888 Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity *via* activation of guanylate cyclase-C in rat models  
*Boulete IM, Thadi A, Beaufrand C, Patwa V, Joshi A, Foss JA, Eddy EP, Eutamene H, Palejwala VA, Theodorou V, Shailubhai K*
- 1901 Mitochondrial pathway mediated by reactive oxygen species involvement in  $\alpha$ -hederin-induced apoptosis in hepatocellular carcinoma cells  
*Li J, Wu DD, Zhang JX, Wang J, Ma JJ, Hu X, Dong WG*

#### Retrospective Study

- 1911 Usefulness of three-dimensional visualization technology in minimally invasive treatment for infected necrotizing pancreatitis  
*Wang PF, Liu ZW, Cai SW, Su JJ, He L, Feng J, Xin XL, Lu SC*

### CASE REPORT

- 1919 Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-naïve chronic hepatitis B: A case report and review of the literature  
*Cho WH, Lee HJ, Bang KB, Kim SB, Song IH*

## ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Khaled Ali Jadallah, MD, Associate Professor, Doctor, Department of Internal Medicine, King Abdullah University Hospital, Jordan University of Science and Technology, Irbid 22110, Jordan

## AIMS AND SCOPE

*World Journal of Gastroenterology* (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7<sup>th</sup>, 14<sup>th</sup>, 21<sup>st</sup>, and 28<sup>th</sup> each month. The *WJG* Editorial Board consists of 642 experts in gastroenterology and hepatology from 59 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

## INDEXING/ABSTRACTING

*World Journal of Gastroenterology* (*WJG*) is now indexed in Current Contents<sup>®</sup>/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch<sup>®</sup>), Journal Citation Reports<sup>®</sup>, Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2017 edition of Journal Citation Reports<sup>®</sup> cites the 2016 impact factor for *WJG* as 3.365 (5-year impact factor: 3.176), ranking *WJG* as 29<sup>th</sup> among 79 journals in gastroenterology and hepatology (quartile in category Q2).

## EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*  
Responsible Electronic Editor: *Yan Huang*  
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Fang-Fang Ji*  
Proofing Editorial Office Director: *Ze-Mao Gong*

NAME OF JOURNAL  
*World Journal of Gastroenterology*

ISSN  
ISSN 1007-9327 (print)  
ISSN 2219-2840 (online)

LAUNCH DATE  
October 1, 1995

FREQUENCY  
Weekly

EDITORS-IN-CHIEF  
**Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon**, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

**Stephen C Strom, PhD, Professor**, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

**Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology**, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

EDITORIAL BOARD MEMBERS  
All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

EDITORIAL OFFICE  
**Ze-Mao Gong, Director**  
*World Journal of Gastroenterology*  
Baishideng Publishing Group Inc  
7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [editorialoffice@wjgnet.com](mailto:editorialoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

PUBLISHER  
Baishideng Publishing Group Inc  
7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

PUBLICATION DATE  
May 7, 2018

COPYRIGHT  
© 2018 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT  
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS  
Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION  
<http://www.f6publishing.com>

## Olfactomedin-4 in digestive diseases: A mini-review

Xin-Yu Wang, Sheng-Hui Chen, Ya-Nan Zhang, Cheng-Fu Xu

Xin-Yu Wang, Sheng-Hui Chen, Department of Gastroenterology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China

Ya-Nan Zhang, Department of Geriatrics, Zhejiang Provincial People's Hospital, Hangzhou 310014, Zhejiang Province, China

Cheng-Fu Xu, Department of Gastroenterology, Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China

ORCID number: Xin-Yu Wang (0000-0002-7301-3991); Sheng-Hui Chen (0000-0002-7470-8883); Ya-Nan Zhang (0000-0002-5985-5906); Cheng-Fu Xu (0000-0002-6172-1253).

**Author contributions:** All authors contributed equally to this paper through the conception and design of the study, literature review and analysis, drafting, critical revision and editing, and approval of the final version.

**Supported by** the National Natural Science Foundation of China, No. 81470838; and the Science Foundation of Health Bureau of Zhejiang Province, No. 2015KYB030.

**Conflict-of-interest statement:** No potential conflicts of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to:** Cheng-Fu Xu, MD, Associate Professor, Department of Gastroenterology, the First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China. [xiaofu@zju.edu.cn](mailto:xiaofu@zju.edu.cn)  
Telephone: +86-571-87236863

Fax: +86-571-87236611

Received: March 11, 2018

Peer-review started: March 12, 2018

First decision: March 29, 2018

Revised: April 6, 2018

Accepted: April 9, 2018

Article in press: April 9, 2018

Published online: May 7, 2018

### Abstract

Olfactomedin-4 (OLFM4, GW112, hGC-1) is a glycoprotein belonging to the olfactomedin family. The expression of OLFM4 is strong in the small intestine, colon and prostate, and moderate in the stomach and bone marrow. Previous studies have revealed that OLFM4 is closely associated with many digestive diseases. Up-regulation of OLFM4 has been detected in the *Helicobacter pylori* (*H. pylori*)-infected gastric mucosa, inflammatory bowel disease tissue and gastrointestinal malignancies, including gastric cancer, colorectal cancer, pancreatic cancer and gallbladder cancer. Down-regulation of OLFM4 has also been detected in some cases, such as in poorly differentiated, advanced-stage and metastatic tumors. Studies using OLFM4-deficient mouse models have revealed that OLFM4 acts as a negative regulator of *H. pylori*-specific immune responses and plays an important role in mucosal defense in inflammatory bowel disease. Patients with OLFM4-positive gastric cancer or colorectal cancer have a better survival rate than OLFM4-negative patients. However, the prognosis is worse in pancreatic cancer patients with high levels of expression of OLFM4. The NF- $\kappa$ B, Notch and Wnt signaling pathways are involved in the regulation of OLFM4 expression in digestive diseases, and its role in pathogenesis is associated with anti-inflammation, apoptosis, cell adhesion and proliferation. OLFM4 may serve as a potential specific diagnostic marker and a therapeutic target in digestive diseases. Further studies are required to explore the clinical value of OLFM4.



**Key words:** Olfactomedin-4; Inflammation; Cancer; *Helicobacter pylori* infection

© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This review is based on the currently available literature about olfactomedin-4 (OLFM4) and is intended to reveal the link between OLFM4 and digestive diseases, including *Helicobacter pylori* infection, inflammatory bowel disease and gastrointestinal malignancies. The data on the expression, function and regulatory pathways of OLFM4 in digestive diseases are summarized. The potential clinical value of OLFM4 in digestive diseases is also discussed.

Wang XY, Chen SH, Zhang YN, Xu CF. Olfactomedin-4 in digestive diseases: A mini-review. *World J Gastroenterol* 2018; 24(17): 1881-1887 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v24/i17/1881.htm> DOI: <http://dx.doi.org/10.3748/wjg.v24.i17.1881>

## INTRODUCTION

Olfactomedin-4 (OLFM4, also called GW112 or hGC-1) is a 72-kDa glycoprotein belonging to the olfactomedin family and is characterized by the presence of an olfactomedin domain with approximately 250 amino acids, which is located in the C-terminal region<sup>[1]</sup>. OLFM4 was initially cloned from human hematopoietic myeloid cells treated with granulocyte colony-stimulating factor<sup>[1]</sup>. The *OLFM4* gene, located on chromosome 13q14.3, encodes a 510-amino acid N-linked glycoprotein with the olfactomedin domain<sup>[1,2]</sup>. OLFM4 can be expressed in the membrane, cytoplasm, nucleus, mitochondria and mature neutrophil granules<sup>[1,3-5]</sup>. OLFM4 is strongly expressed in the small intestine, colon and prostate, moderately expressed in the stomach and bone marrow, and weakly expressed or not expressed in other tissues<sup>[1]</sup>.

Compared with that in normal tissues, aberrant expression of *OLFM4* has been detected in many pathological tissues, such as the gastric mucosa infected with *Helicobacter pylori* (*H. pylori*)<sup>[6,7]</sup>, inflamed intestinal tissue in inflammatory bowel disease<sup>[8,9]</sup> and many types of gastrointestinal malignancies<sup>[10-14]</sup> (Figure 1). The primary function of *OLFM4* in gastrointestinal malignancies is associated with its role as an antiapoptotic factor that promotes the tumor growth<sup>[4]</sup>. In addition, *OLFM4* down-regulates innate immunity against *H. pylori* infection<sup>[7]</sup> and affects the anti-inflammatory function in inflammatory bowel disease<sup>[15]</sup>. In this review, we summarize the data on the expression, function and regulatory pathways of OLFM4 in digestive diseases.

## OLFM4 IN *H. PYLORI* INFECTION

### Expression

*H. pylori* infection is a well-recognized risk factor for

gastric diseases as well as extra-gastric diseases<sup>[16-18]</sup>. The host immune response plays a key role in the course and outcome of *H. pylori* infection<sup>[19,20]</sup>. The innate immune system serves as the first line of defense against *H. pylori* infection<sup>[21]</sup>. An adaptive immune response to *H. pylori* is also elicited in nearly all *H. pylori*-infected individuals<sup>[22]</sup>. OLFM4 is a novel glycoprotein that negatively regulates the host defense system against bacterial infection<sup>[23]</sup>.

An early microarray study found that OLFM4 expression is significantly up-regulated in the gastric mucosa of *H. pylori*-infected patients compared with that in uninfected controls<sup>[6]</sup>. OLFM4 expression was also found to be significantly up-regulated in the gastric mucosa of *H. pylori*-infected mice. However, further study is warranted to determine whether eradication of *H. pylori* leads to the normalization of OLFM4 levels. The expression of OLFM4 is up-regulated in neutrophils, macrophages and epithelial cells after *H. pylori* infection, which suggests that overexpression of OLFM4 upon *H. pylori* infection is due to its direct action on epithelial cells as well as to activation of neutrophil and macrophage infiltration<sup>[7]</sup>, thus suggesting a potential role for OLFM4 in the host immune response against *H. pylori* infection.

### Function


The exact function of OLFM4 in *H. pylori* infection has been demonstrated by generating an OLFM4-deficient mouse model. Colonization of *H. pylori* in the gastric mucosa is significantly reduced after knocking out the *OLFM4* gene, as compared with that in wild-type mice<sup>[7]</sup>. In addition, in response to *H. pylori* infection, infiltration of inflammatory cells was significantly enhanced, the production of proinflammatory cytokines and chemokines was increased, and the bacterial load was reduced in OLFM4-deficient mice<sup>[7]</sup>. Therefore, OLFM4 acts as a negative regulator of the *H. pylori*-specific immune responses<sup>[7]</sup>.

### Regulation

*OLFM4* is a target gene of the NF-κB pathway and expression of the *OLFM4* gene can be regulated by the transcription factor NF-κB<sup>[7,24]</sup>. The regulation is achieved by binding of NF-κB to the 5'-upstream region of the *OLFM4* gene<sup>[24]</sup>. Moreover, OLFM4 exerts a negative feedback effect on the NF-κB pathway<sup>[7]</sup>.

Mouse experiments have revealed that *H. pylori* infection up-regulates the OLFM4 expression in an NF-κB-dependent manner, and then, due to the negative feedback effect of OLFM4, the *H. pylori*-induced NF-κB activation is down-regulated<sup>[7]</sup>. Furthermore, OLFM4 inhibits the nucleotide oligomerization domain (NOD)-1/2-mediated NF-κB activation and subsequent cytokine and chemokine production through direct association with NOD1 and NOD2<sup>[7]</sup>. The reduced cytokine and chemokine production results in a weak inflammatory response and a high level of colonization of *H. pylori* in the gastric mucosa<sup>[7]</sup>.

Experiments in a MyD88 and OLFM4 double-



**Figure 1 Relationship between olfactomedin-4 and digestive diseases.** Olfactomedin-4 is related to *Helicobacter pylori* infection, inflammatory bowel disease and gastrointestinal malignancies, including gastric cancer, colorectal cancer, pancreatic cancer and gallbladder cancer.

knockout mouse model have demonstrated that the *H. pylori* colonization level in the model is similar to that in wild-type mice<sup>[25]</sup>. Even though the immune and inflammatory responses are enhanced compared with those in wild-type mice, infiltration of inflammatory cells in the gastric mucosa of double-knockout mice is lower than that in OLFM4 knockout mice<sup>[25]</sup>. Additionally, knocking out OLFM4 significantly up-regulates the MyD88 expression. It has been shown that deletion of OLFM4 indirectly increases the MyD88 expression by enhancing NOD2 expression, whereas the deficiency of MyD88 leads to a loss of the feedback inhibition of the NF- $\kappa$ B pathway and of the resulting response<sup>[25,26]</sup>.

## OLFM4 IN INFLAMMATORY BOWEL DISEASE

### Expression

OLFM4 is a robust marker for murine intestinal stem cells as well as human intestinal stem cells<sup>[27]</sup>. Both OLFM4 mRNA and protein expression levels are significantly up-regulated in the intestinal epithelium in Crohn's disease and ulcerative colitis<sup>[8,9]</sup>. Compared with

that in inflamed tissue from Crohn's disease patients, the OLFM4 expression is more obviously increased in inflamed tissue from patients with active ulcerative colitis<sup>[8,9]</sup>. Moreover, in active ulcerative colitis, the expression of OLFM4 expands to the surface of epithelial cells as well as to the crypt lumen, and OLFM4 seems to be secreted into the mucus<sup>[8,9]</sup>. In contrast, the *OLFM4* gene expression is almost absent in luminal surface cells and mesenchymal cells and is confined to the lower third of the crypt in normal tissues<sup>[8,9]</sup>.

### Function

OLFM4 plays an important role in the mucosal defense of the stomach and colon<sup>[9]</sup>. Experiments using OLFM4-deficient mice have revealed severe inflammation and proliferation in intestinal crypts in small intestines<sup>[15]</sup>. Serious inflammation and mucosa damage have also been found in the colon of OLFM4-deficient mice<sup>[15]</sup>.

The anti-inflammatory function of OLFM4 in inflammatory bowel disease is consistent with that in the stomach. The function against inflammatory bowel disease may be related to the tissue-specific human beta-defensins (HBD)1, HBD2 and HBD3. As mucus

components with different electric charges, OLFM4 and HBD1–3 can interact, and the binding ability of OLFM4 was ranked, from high to low, as HBD3 > HBD2 > HBD1<sup>[9]</sup>. Furthermore, OLFM4 binding leads to a decrease in the antimicrobial activities of HBD1–3<sup>[9]</sup>.

### Regulation

OLF4 is a target gene for the Notch signaling pathway, which regulates intestinal cell proliferation and differentiation<sup>[28]</sup>. The expression of OLF4 increases after activation of Notch signaling<sup>[28]</sup>. Conversely, the expression of OLF4 rapidly decreases after treatment with the Notch blocker dibenzazepine<sup>[9,28]</sup>. Researchers have found that after mesenchymal stem cell transplantation, the expression of OLF4 is down-regulated, while that of Atoh1 is up-regulated<sup>[29]</sup>. This result suggests that the suppression of Notch signaling leads to decreased OLF4 expression.

Although some studies have shown that cell incubation with TNF- $\alpha$  alone does not influence the OLF4 expression, some other studies have found that TNF- $\alpha$  and components of the Notch pathways synergistically up-regulate the OLF4 expression<sup>[9,30,31]</sup>. TNF- $\alpha$  is one of the most important proinflammatory cytokines promoting inflammatory bowel disease<sup>[30]</sup>. Microarray analysis has revealed that up to 21 genes are involved in the synergistic up-regulation of TNF- $\alpha$  and the Notch intracellular domain<sup>[30]</sup>. Further studies have suggested a markedly increased expression of OLF4, reaching up to a 2500-fold increase in LS174T cells, when overexpression of Notch intracellular domain-1 (NICD1) or hairy and enhancer of split-1 (HES1) is combined with TNF- $\alpha$  stimulation<sup>[30,31]</sup>. Such a synergistic effect is mediated through transcriptional regulation, which is dependent on a proximal NF- $\kappa$ B binding site<sup>[31]</sup>.

## OLF4 IN GASTROINTESTINAL CANCER

Increased OLF4 expression has been reported in some gastrointestinal cancers, such as gastric cancer<sup>[10,11,32,33]</sup>, pancreatic cancer<sup>[12]</sup> and early-stage colon cancer<sup>[13,14]</sup>. In addition, the expression of OLF4 is correlated with the histological type of cancer, differentiation, lymphatic metastasis and prognosis<sup>[10,11,34]</sup>. Furthermore, OLF4 is relevant to many cellular processes, including cell adhesion, apoptosis and proliferation<sup>[2,11,35]</sup>. Therefore, OLF4 may serve as a candidate biomarker for these gastrointestinal cancers<sup>[36]</sup>. Here, we briefly summarize the recent advances in the expression, function and regulation of OLF4 in gastrointestinal cancers.

### Gastric cancer

Up-regulated OLF4 expression is a frequent event in the gastric mucosa in gastric cancer<sup>[10,11,32,33]</sup>. Highly expressed OLF4 is found in intestinal-type adenocarcinoma, while OLF4 expression does not occur in diffuse-type adenocarcinoma<sup>[10]</sup>. Moreover, enhanced expression of OLF4 occurs in well- or moderately differentiated and early-stage adenocarcinomas, and

the expression is remarkably decreased or even lost in poorly differentiated and advanced-stage gastric cancer<sup>[10]</sup>. Furthermore, the OLF4 expression is higher in patients without lymphatic metastasis than in those with lymphatic invasion<sup>[11,37]</sup>. OLF4 expression is also related to the prognosis. OLF4-positive gastric cancer patients have a better survival rate than do OLF4-negative patients<sup>[34,37]</sup>. Using serum OLF4 alone or in combination with human regenerating protein IV as biomarkers for gastric cancer patients is more sensitive than using CA199<sup>[32]</sup>. Down-regulation of OLF4 suppresses the tumor proliferation, migration and invasion of gastric cancer cells *in vitro*<sup>[33,38]</sup>.

The OLF4 gene was found to be up-regulated *via* the NF- $\kappa$ B signaling pathway and to exert an antiapoptotic effect in gastric cancer<sup>[39]</sup>. The antiapoptotic effect caused by OLF4 can be induced by reducing H<sub>2</sub>O<sub>2</sub> or TNF- $\alpha$ <sup>[38]</sup>. Moreover, the antiapoptotic factor OLF4 is a direct target of miR-486, which is a frequently lost microRNA (miRNA) in gastric cancer patients and may act as a tumor suppressor miRNA in gastric cancer<sup>[40]</sup>. miR-486 directly targets and inhibits OLF4 and thereby induces antioncogenic effects against gastric cancer<sup>[40]</sup>.

### Colorectal cancer

OLF4 is enriched in human colon crypts, although it is not expressed in the murine colon<sup>[15,27,41,42]</sup>. It has been universally accepted that OLF4 is a useful marker of intestinal stem cells (ISCs) in humans, similar to LGR5, which is a confirmed ISC marker<sup>[27,43,44]</sup>. Up-regulation of OLF4 is detected more frequently in highly differentiated and early-stage colon cancers than in the normal colon mucosa, whereas it is often down-regulated or not expressed in poorly differentiated, late tumor-node-metastasis stage, and metastatic cancers<sup>[35]</sup>. OLF4-positive colorectal cancer patients have a better survival rate than do OLF4-negative patients<sup>[45]</sup>. In addition, precancerous colorectal lesions also show aberrant OLF4 expression. For example, OLF4 is expressed in a diffuse manner in traditional serrated adenomas, while other ISC markers such as LGR5 and ASCL2 are localized as in normal tissue<sup>[44]</sup>. OLF4 silencing enhances the proliferation in intestinal crypts and inflammation initiated by azoxymethane/dextran sodium sulfate<sup>[15]</sup>. Moreover, systemic OLF4 deletion promotes colon tumorigenesis, which may be associated with the loss of mucosal neutrophils<sup>[15]</sup>.

There is an intimate connection between OLF4, Wnt/ $\beta$ -catenin signaling, crypt biology<sup>[15,46–48]</sup> and colon cancer<sup>[27,49,50]</sup>. OLF4 is a target gene that acts as a negative regulator of the Wnt/ $\beta$ -catenin signaling pathway and inhibits colon cancer progression by down-regulating the Wnt signaling pathway<sup>[15]</sup>.

### Pancreatic cancer

OLF4 mRNA is expressed at higher levels in pancreatic cancer tissues than in noncancerous pancreatic tissue samples<sup>[12]</sup>. In addition, OLF4 was found to be

**Table 1** Effects of olfactomedin-4 in digestive diseases

Disease	Expression	Function	Regulation
<i>H. pylori</i> infection	Up-regulated in the <i>H. pylori</i> -infected gastric mucosa	Negative regulator of <i>H. pylori</i> -specific immune responses	NF- $\kappa$ B, NOD-1/2, MyD88
Inflammatory bowel disease	Up-regulated in the intestinal epithelium in Crohn's disease and ulcerative colitis	Mucosal defense, anti-inflammatory effects	Notch, TNF- $\alpha$
Gastrointestinal malignancies	Up-regulated in well/moderately differentiated, early-stage gastrointestinal malignancies without lymphatic metastasis	Biomarker, candidate therapeutic target	NF- $\kappa$ B, TNF- $\alpha$ , miR-486, Wnt/ $\beta$ -catenin

*H. pylori*: *Helicobacter pylori*.

significantly over-expressed in peripheral blood mononuclear cells in pancreatic cancer patients compared with its expression in a control group<sup>[51]</sup>. Furthermore, OLFM4 has also been detected in pancreatic juice and ascites<sup>[52]</sup>. Pancreatic cancer may occur in a background of chronic pancreatitis. Whether OLFM4 is associated with chronic pancreatitis or acute pancreatitis flares is worth further investigation. In the PANC-1 cell line, OLFM4 is especially increased during the early S phase of the cell cycle and promotes proliferation by supporting the S to G2/M phase transition<sup>[12]</sup>. OLFM4 binds to the apoptosis-promoting factor GRIM-19 to induce antiapoptosis<sup>[4]</sup>. Pancreatic cancer patients with high levels of OLFM4 expression have a worse prognosis<sup>[53]</sup>.

### Gallbladder cancer

Similar to the above findings, expression of the *OLFM4* gene has been found to be increased in gallbladder cancer tissues<sup>[54]</sup>. In addition, the expression level of OLFM4 is significantly related to the age of gallbladder cancer patients<sup>[54]</sup>. However, further studies are needed to clarify the precise role of OLFM4 in gallbladder cancer.

## CONCLUSION

Since the initial discovery of OLFM4, researchers have explored many aspects of OLFM4, including its aberrant expression, biological functions and related mechanisms (Table 1). The expression of OLFM4 has been relatively well studied in normal tissues as well as in numerous diseases. The anti-inflammatory and antiapoptotic roles of OLFM4 are generally accepted. However, the exact mechanism for its effects in gastrointestinal diseases remains to be determined. Moreover, the clinical applications of OLFM4 as a specific detection marker or a therapeutic target need to be defined in the future.

## REFERENCES

- Zhang J, Liu WL, Tang DC, Chen L, Wang M, Pack SD, Zhuang Z, Rodgers GP. Identification and characterization of a novel member of olfactomedin-related protein family, hGC-1, expressed during myeloid lineage development. *Gene* 2002; **283**: 83-93 [PMID: 11867215 DOI: 10.1016/S0378-1119(01)00763-6]
- Liu W, Chen L, Zhu J, Rodgers GP. The glycoprotein hGC-1 binds to cadherin and lectins. *Exp Cell Res* 2006; **312**: 1785-1797 [PMID: 16566923 DOI: 10.1016/j.yexcr.2006.02.011]
- Liu W, Lee HW, Liu Y, Wang R, Rodgers GP. Olfactomedin 4 is a novel target gene of retinoic acids and 5-aza-2'-deoxycytidine involved in human myeloid leukemia cell growth, differentiation, and apoptosis. *Blood* 2010; **116**: 4938-4947 [PMID: 20724538 DOI: 10.1182/blood-2009-10-246439]
- Zhang X, Huang Q, Yang Z, Li Y, Li CY. GW112, a novel antiapoptotic protein that promotes tumor growth. *Cancer Res* 2004; **64**: 2474-2481 [PMID: 15059901 DOI: 10.1158/0008-5472.CAN-03-3443]
- Liu W, Yan M, Liu Y, McLeish KR, Coleman WG Jr, Rodgers GP. Olfactomedin 4 inhibits cathepsin C-mediated protease activities, thereby modulating neutrophil killing of *Staphylococcus aureus* and *Escherichia coli* in mice. *J Immunol* 2012; **189**: 2460-2467 [PMID: 22844115 DOI: 10.4049/jimmunol.1103179]
- Mannick EE, Schurr JR, Zapata A, Lentz JJ, Gastanaduy M, Cote RL, Delgado A, Correa P, Correa H. Gene expression in gastric biopsies from patients infected with *Helicobacter pylori*. *Scand J Gastroenterol* 2004; **39**: 1192-1200 [PMID: 15742995 DOI: 10.1080/00365520410003588]
- Liu W, Yan M, Liu Y, Wang R, Li C, Deng C, Singh A, Coleman WG Jr, Rodgers GP. Olfactomedin 4 down-regulates innate immunity against *Helicobacter pylori* infection. *Proc Natl Acad Sci U S A* 2010; **107**: 11056-11061 [PMID: 20534456 DOI: 10.1073/pnas.1001269107]
- Shinozaki S, Nakamura T, Iimura M, Kato Y, Iizuka B, Kobayashi M, Hayashi N. Upregulation of Reg 1alpha and GW112 in the epithelium of inflamed colonic mucosa. *Gut* 2001; **48**: 623-629 [PMID: 11302958 DOI: 10.1136/gut.48.5.623]
- Gersemann M, Becker S, Nuding S, Antoni L, Ott G, Fritz P, Oue N, Yasui W, Wehkamp J, Stange EF. Olfactomedin-4 is a glycoprotein secreted into mucus in active IBD. *J Crohns Colitis* 2012; **6**: 425-434 [PMID: 22398066 DOI: 10.1016/j.crohns.2011.09.013]
- Liu W, Zhu J, Cao L, Rodgers GP. Expression of hGC-1 is correlated with differentiation of gastric carcinoma. *Histopathology* 2007; **51**: 157-165 [PMID: 17650212 DOI: 10.1111/j.1365-2559.2007.02763.x]
- Grover PK, Hardingham JE, Cummins AG. Stem cell marker olfactomedin 4: critical appraisal of its characteristics and role in tumorigenesis. *Cancer Metastasis Rev* 2010; **29**: 761-775 [PMID: 20878207 DOI: 10.1007/s10555-010-9262-z]
- Kobayashi D, Koshida S, Moriai R, Tsuji N, Watanabe N. Olfactomedin 4 promotes S-phase transition in proliferation of pancreatic cancer cells. *Cancer Sci* 2007; **98**: 334-340 [PMID: 17270022 DOI: 10.1111/j.1349-7006.2007.00397.x]
- Koshida S, Kobayashi D, Moriai R, Tsuji N, Watanabe N. Specific overexpression of OLFM4(GW112/HGC-1) mRNA in colon, breast and lung cancer tissues detected using quantitative analysis. *Cancer Sci* 2007; **98**: 315-320 [PMID: 17270020 DOI: 10.1111/j.1349-7006.2006.00383.x]
- Duan C, Liu X, Liang S, Yang Z, Xia M, Wang L, Chen S, Yu L. Oestrogen receptor-mediated expression of Olfactomedin 4 regulates the progression of endometrial adenocarcinoma. *J Cell Mol Med* 2014; **18**: 863-874 [PMID: 24495253 DOI: 10.1111/jcmm.12232]
- Liu W, Li H, Hong SH, Piszczek GP, Chen W, Rodgers GP. Olfactomedin 4 deletion induces colon adenocarcinoma in *Apc*<sup>Min/+</sup> mice. *Oncogene* 2016; **35**: 5237-5247 [PMID: 26973250 DOI: 10.1038/onc.2016.111]



- 10.1038/onc.2016.58]
- 16 **Malfertheiner P**, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; European Helicobacter Study Group. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. *Gut* 2012; **61**: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]
  - 17 **McColl KE**. Clinical practice. Helicobacter pylori infection. *N Engl J Med* 2010; **362**: 1597-1604 [PMID: 20427808 DOI: 10.1056/NEJMcpl001110]
  - 18 **Sung KC**, Rhee EJ, Ryu SH, Beck SH. Prevalence of Helicobacter pylori infection and its association with cardiovascular risk factors in Korean adults. *Int J Cardiol* 2005; **102**: 411-417 [PMID: 16004885 DOI: 10.1016/j.ijcard.2004.05.040]
  - 19 **Kusters JG**, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. *Clin Microbiol Rev* 2006; **19**: 449-490 [PMID: 16847081 DOI: 10.1128/CMR.00054-05]
  - 20 **Borody T**, Ren Z, Pang G, Clancy R. Impaired host immunity contributes to Helicobacter pylori eradication failure. *Am J Gastroenterol* 2002; **97**: 3032-3037 [PMID: 12492186 DOI: 10.1111/j.1572-0241.2002.07121.x]
  - 21 **Algood HM**, Gallo-Romero J, Wilson KT, Peek RM Jr, Cover TL. Host response to Helicobacter pylori infection before initiation of the adaptive immune response. *FEMS Immunol Med Microbiol* 2007; **51**: 577-586 [PMID: 17919297 DOI: 10.1111/j.1574-695X.2007.00338.x]
  - 22 **Portal-Celhay C**, Perez-Perez GI. Immune responses to Helicobacter pylori colonization: mechanisms and clinical outcomes. *Clin Sci (Lond)* 2006; **110**: 305-314 [PMID: 16464172 DOI: 10.1042/CS20050232]
  - 23 **Liu W**, Yan M, Sugui JA, Li H, Xu C, Joo J, Kwon-Chung KJ, Coleman WG, Rodgers GP. Olfm4 deletion enhances defense against Staphylococcus aureus in chronic granulomatous disease. *J Clin Invest* 2013; **123**: 3751-3755 [PMID: 23908114 DOI: 10.1172/JCI68453]
  - 24 **Chin KL**, Aerbajinai W, Zhu J, Drew L, Chen L, Liu W, Rodgers GP. The regulation of OLFM4 expression in myeloid precursor cells relies on NF-kappaB transcription factor. *Br J Haematol* 2008; **143**: 421-432 [PMID: 18764868 DOI: 10.1111/j.1365-2141.2008.07368.x]
  - 25 **Yan M**, Liu WL, Joo J, Sun JF, Datta S, Yang A, Rodgers G, Coleman WG. MyD88 Has a Key Role for OLFM4, a Novel Anti-Inflammatory Mediator in H. pylori Infection. *Gastroenterology* 2012; **142**: S-686 [DOI: 10.1016/S0016-5085(12)62645-6]
  - 26 **Yan M**, Liu W, Xu C, Joo J, Yu C, Zhu Y, Yan S, Rodgers G, Coleman WG. Olfactomedin 4 Deletion Enhances Host Pro-Inflammatory Immune Responses Against Helicobacter pylori Infection Through a MyD88 Dependent Mechanism. *Gastroenterology* 2014; **146**: S287-S288 [DOI: 10.1016/S0016-5085(14)61021-0]
  - 27 **van der Flier LG**, Haegebarth A, Stange DE, van de Wetering M, Clevers H. OLFM4 is a robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells. *Gastroenterology* 2009; **137**: 15-17 [PMID: 19450592 DOI: 10.1053/j.gastro.2009.05.035]
  - 28 **VanDussen KL**, Carulli AJ, Keeley TM, Patel SR, Puthoff BJ, Magness ST, Tran IT, Maillard I, Siebel C, Kolterud A, Grosse AS, Gumucio DL, Ernst SA, Tsai YH, Dempsey PJ, Samuelson LC. Notch signaling modulates proliferation and differentiation of intestinal crypt base columnar stem cells. *Development* 2012; **139**: 488-497 [PMID: 22190634 DOI: 10.1242/dev.070763]
  - 29 **Xing Y**, Chen X, Cao Y, Huang J, Xie X, Wei Y. Expression of Wnt and Notch signaling pathways in inflammatory bowel disease treated with mesenchymal stem cell transplantation: evaluation in a rat model. *Stem Cell Res Ther* 2015; **6**: 101 [PMID: 25998108 DOI: 10.1186/s13287-015-0092-3]
  - 30 **Kawamoto A**, Nakata T, Fujii S, Suzuki K, Ishibashi F, Tsuchiya K, Nakamura T, Okamoto R, Watanabe M. Notch Signaling and TNF-alpha Synergistically Up-regulate Stem Cell-Specific Genes, OLFM4 and UBD, in the Inflamed Intestinal Epithelia of IBD Patients. *Inflamm Bowel Dis* 2017; **23**: S92-S92 [DOI: 10.1097/01.MIB.0000512827.36560.28]
  - 31 **Okamoto R**, Akiyama J, Murano T, Shimizu H, Tsuchiya K, Nakamura T, Watanabe M. Notch-Hes1 Pathway and TNF- $\alpha$  Synergistically up-Regulates OLFM4 Expression in the Inflamed Mucosa of the Human Intestine. *Gastroenterology* 2011; **140**: S-173 [DOI: 10.1016/S0016-5085(11)60699-9]
  - 32 **Oue N**, Sentani K, Noguchi T, Ohara S, Sakamoto N, Hayashi T, Anami K, Motoshita J, Ito M, Tanaka S, Yoshida K, Yasui W. Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients. *Int J Cancer* 2009; **125**: 2383-2392 [PMID: 19670418 DOI: 10.1002/ijc.24624]
  - 33 **Ran X**, Xu X, Yang Y, She S, Yang M, Li S, Peng H, Ding X, Hu H, Hu P, Zhang D, Ren H, Wu L, Zeng W. A quantitative proteomics study on olfactomedin 4 in the development of gastric cancer. *Int J Oncol* 2015; **47**: 1932-1944 [PMID: 26398045 DOI: 10.3892/ijo.2015.3168]
  - 34 **Oue N**, Sentani K, Sakamoto N, Yasui W. Clinicopathologic and molecular characteristics of gastric cancer showing gastric and intestinal mucin phenotype. *Cancer Sci* 2015; **106**: 951-958 [PMID: 26033320 DOI: 10.1111/cas.12706]
  - 35 **Liu W**, Liu Y, Zhu J, Wright E, Ding I, Rodgers GP. Reduced hGC-1 protein expression is associated with malignant progression of colon carcinoma. *Clin Cancer Res* 2008; **14**: 1041-1049 [PMID: 18281536 DOI: 10.1158/1078-0432.CCR-07-4125]
  - 36 **Guette C**, Valo I, Vétillard A, Coqueret O. Olfactomedin-4 is a candidate biomarker of solid gastric, colorectal, pancreatic, head and neck, and prostate cancers. *Proteomics Clin Appl* 2015; **9**: 58-63 [PMID: 25400027 DOI: 10.1002/prca.201400083]
  - 37 **Luo Z**, Zhang Q, Zhao Z, Li B, Chen J, Wang Y. OLFM4 is associated with lymph node metastasis and poor prognosis in patients with gastric cancer. *J Cancer Res Clin Oncol* 2011; **137**: 1713-1720 [PMID: 21904905 DOI: 10.1007/s00432-011-1042-9]
  - 38 **Liu RH**, Yang MH, Xiang H, Bao LM, Yang HA, Yue LW, Jiang X, Ang N, Wu LY, Huang Y. Depletion of OLFM4 gene inhibits cell growth and increases sensitization to hydrogen peroxide and tumor necrosis factor-alpha induced-apoptosis in gastric cancer cells. *J Biomed Sci* 2012; **19**: 38 [PMID: 22471589 DOI: 10.1186/1423-0127-19-38]
  - 39 **Kim KK**, Park KS, Song SB, Kim KE. Up regulation of GW112 Gene by NF kappaB promotes an antiapoptotic property in gastric cancer cells. *Mol Carcinog* 2010; **49**: 259-270 [PMID: 19908244 DOI: 10.1002/mc.20596]
  - 40 **Oh HK**, Tan AL, Das K, Ooi CH, Deng NT, Tan IB, Beillard E, Lee J, Ramnarayanan K, Rha SY, Palanisamy N, Voorhoeve PM, Tan P. Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer. *Clin Cancer Res* 2011; **17**: 2657-2667 [PMID: 21415212 DOI: 10.1158/1078-0432.CCR-10-3152]
  - 41 **Kosinski C**, Li VS, Chan AS, Zhang J, Ho C, Tsui WY, Chan TL, Mifflin RC, Powell DW, Yuen ST, Leung SY, Chen X. Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. *Proc Natl Acad Sci USA* 2007; **104**: 15418-15423 [PMID: 17881565 DOI: 10.1073/pnas.0707210104]
  - 42 **van der Flier LG**, van Gijn ME, Hatzis P, Kujala P, Haegebarth A, Stange DE, Begthel H, van den Born M, Guryev V, Oving I, van Es JH, Barker N, Peters PJ, van de Wetering M, Clevers H. Transcription factor achaete scute-like 2 controls intestinal stem cell fate. *Cell* 2009; **136**: 903-912 [PMID: 19269367 DOI: 10.1016/j.cell.2009.01.031]
  - 43 **Jang BG**, Lee BL, Kim WH. Intestinal Stem Cell Markers in the Intestinal Metaplasia of Stomach and Barrett's Esophagus. *PLoS One* 2015; **10**: e0127300 [PMID: 25996368 DOI: 10.1371/journal.pone.0127300]
  - 44 **Jang BG**, Kim HS, Kim KJ, Rhee YY, Kim WH, Kang GH. Distribution of intestinal stem cell markers in colorectal precancerous lesions. *Histopathology* 2016; **68**: 567-577 [PMID: 26212207 DOI: 10.1111/his.12787]
  - 45 **Seko N**, Oue N, Noguchi T, Sentani K, Sakamoto N, Hinoi T,

- Okajima M, Yasui W. Olfactomedin 4 (GW112, hGC-1) is an independent prognostic marker for survival in patients with colorectal cancer. *Exp Ther Med* 2010; **1**: 73-78 [PMID: 23136596 DOI: 10.3892/etm.00000013]
- 46 **Kuhnert F**, Davis CR, Wang HT, Chu P, Lee M, Yuan J, Nusse R, Kuo CJ. Essential requirement for Wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression of Dickkopf-1. *Proc Natl Acad Sci U S A* 2004; **101**: 266-271 [PMID: 14695885 DOI: 10.1073/pnas.2536800100]
- 47 **Pinto D**, Gregorieff A, Begthel H, Clevers H. Canonical Wnt signals are essential for homeostasis of the intestinal epithelium. *Genes Dev* 2003; **17**: 1709-1713 [PMID: 12865297 DOI: 10.1101/gad.267103]
- 48 **Korinek V**, Barker N, Moerer P, van Donselaar E, Huls G, Peters PJ, Clevers H. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. *Nat Genet* 1998; **19**: 379-383 [PMID: 9697701 DOI: 10.1038/1270]
- 49 **Korinek V**, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. *Science* 1997; **275**: 1784-1787 [PMID: 9065401 DOI: 10.1126/science.275.5307.1784]
- 50 **Morin PJ**, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. *Science* 1997; **275**: 1787-1790 [PMID: 9065402 DOI: 10.1126/science.275.5307.1787]
- 51 **Yan H**, Lu D, Xu L, Xie Q, Dong X, Wu Y. Increased expression level of Olfactomedin4 in peripheral blood mononuclear cells of pancreatic adenocarcinoma patients. *Hepatogastroenterology* 2011; **58**: 1354-1359 [PMID: 21937407 DOI: 10.5754/hge10623]
- 52 **Makawita S**, Smith C, Batruch I, Zheng Y, Rückert F, Grützmann R, Pilarsky C, Gallinger S, Diamandis EP. Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers. *Mol Cell Proteomics* 2011; **10**: M111.008599 [PMID: 21653254 DOI: 10.1074/mcp.M111.008599]
- 53 **Takadate T**, Onogawa T, Fukuda T, Motoi F, Suzuki T, Fujii K, Kihara M, Mikami S, Bando Y, Maeda S, Ishida K, Minowa T, Hanagata N, Ohtsuka H, Katayose Y, Egawa S, Nishimura T, Unno M. Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin-fixed paraffin-embedded tissues. *Int J Cancer* 2013; **132**: 1368-1382 [PMID: 22915188 DOI: 10.1002/ijc.27797]
- 54 **Gu X**, Li B, Jiang M, Fang M, Ji J, Wang A, Wang M, Jiang X, Gao C. RNA sequencing reveals differentially expressed genes as potential diagnostic and prognostic indicators of gallbladder carcinoma. *Oncotarget* 2015; **6**: 20661-20671 [PMID: 25970782 DOI: 10.18632/oncotarget.3861]

**P- Reviewer:** Ierardi E, Vorobjova T **S- Editor:** Gong ZM  
**L- Editor:** Filipodia **E- Editor:** Huang Y





Published by **Baishideng Publishing Group Inc**  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>



ISSN 1007-9327

